Identification of mast cells as a candidate significant target of immunotherapy for acute myeloid leukemia
CONCLUSION: The hub genes and drugs have high research value and clinical application in AML therapy. Our study not only provides gene targets and small molecule drugs for AML immunotherapy concerning mast cells but also provides new ideas for researchers to explore immunotherapy targets of other tumors.PMID:33648435 | DOI:10.1080/16078454.2021.1889158 (Source: Hematology)
Source: Hematology - March 2, 2021 Category: Hematology Authors: Mingfeng Jia Hao Zhang Lina Wang Long Zhao Shengxuan Fan Yaming Xi Source Type: research

Impact of pre-transplantation minimal residual disease (MRD) on the outcome of Allogeneic hematopoietic stem cell transplantation for acute leukemia
CONCLUSION: Pre-transplantation MRD positive status is a risk factor for survival and prognosis after HSCT. Upon this, emphasis should be put on (1) screening more efficient chemo regimen with targeted agents, to help patients reach and keep MRD- status before transplantation; (2) designing better management with different GvHD prophylaxis treatment, timely disease monitoring and preemptive intervention on relapse.PMID:33648437 | DOI:10.1080/16078454.2021.1889162 (Source: Hematology)
Source: Hematology - March 2, 2021 Category: Hematology Authors: Xing Shen Jing Pan Chenchen Qi Yuan Feng Hanxin Wu Sixuan Qian Hua Lu Lijuan Chen Jianyong Li Kourong Miao Hairong Qiu Han Zhu Source Type: research

Quality of life in patients with nonvalvular atrial fibrillation treated with oral anticoagulants
CONCLUSION: Patients treated with DOACs report a slightly better quality of life than those treated with VKAs.PMID:33631081 | DOI:10.1080/16078454.2021.1892329 (Source: Hematology)
Source: Hematology - February 25, 2021 Category: Hematology Authors: Miren Gabilondo Jes ús Loza Angel Pereda Ohiane Caballero Nerea Zamora Ania Gorostiza Javier Mar Source Type: research

Persistence to hypomethylating agents and clinical and economic outcomes among patients with myelodysplastic syndromes
Hematology. 2021 Dec;26(1):261-270. doi: 10.1080/16078454.2021.1889161.ABSTRACTOBJECTIVES: To evaluate hypomethylating agent (HMA) persistence in patients with myelodysplastic syndromes (MDS), and examine its association with healthcare resource utilization (HRU) and progression to acute myeloid leukemia (AML).METHODS: A total of 2,400 adults diagnosed with MDS initiating HMAs were included from IBM MarketScan databases during 1/1/2011-3/31/2018. The index date was HMA initiation following MDS diagnosis. Patients were classified according to their persistence status by the end of a fixed 'landmark period' of 4 months post-...
Source: Hematology - February 25, 2021 Category: Hematology Authors: Wendy Y Cheng Ambika Satija Hoi Ching Cheung Kala Hill Tim Wert Fran çois Laliberté Patrick Lefebvre Source Type: research

Myelomonocytic differentiation of leukemic blasts accompanied by differentiation syndrome in a case of < em > FLT3 < /em > -ITD-positive AML treated with gilteritinib
We report a case of relapsed AML with FLT3-ITD that was treated with gilteritinib. Analysis of the FLT3-ITD variant allele frequency (VAF) revealed that FLT3-ITD VAF was not decreased despite achievement of complete remission with incomplete hematologic recovery. Remarkable increases of monocytes and granulocytes accompanied by differentiation syndrome were observed at 6 months after the initiation of gilteritinib treatment. Intermittent chemotherapy with low-dose cytarabine and mitoxantrone was effective for reducing myelomonocytosis and resolving differentiation syndrome.PMID:33631087 | DOI:10.1080/16078454.2021.1889111 (Source: Hematology)
Source: Hematology - February 25, 2021 Category: Hematology Authors: Takeshi Kondo Masahiro Onozawa Shinichi Fujisawa Shinpei Harada Reiki Ogasawara Koh Izumiyama Makoto Saito Masanobu Morioka Akio Mori Takanori Teshima Source Type: research

Safety and efficacy of different doses of anthracyclines combined with arsenic trioxide and all-trans retinoic acid in the treatment of de novo acute promyelocytic leukemia
Hematology. 2021 Dec;26(1):271-276. doi: 10.1080/16078454.2021.1889159.ABSTRACTOBJECTIVES: The purpose of this study was to evaluate the efficacy and safety of different doses of anthracyclines combined with arsenic trioxide (ATO) and all-trans retinoic acid (ATRA) for induction in newly diagnosed acute promyelocytic leukemia (APL).METHODS: One hundred and forty patients were included between January 2011 and December 2017. Seventy patients received low dose anthracycline, ATO and ATRA for induction chemotherapy; and other seventy patients received standard dose anthracycline, ATO and ATRA for induction chemotherapy.RESULT...
Source: Hematology - February 25, 2021 Category: Hematology Authors: Yaxue Wu Peng Ke Haixia Zhou Depei Wu Suning Chen Huiying Qiu Yue Han Caixia Li Xiao Ma Aining Sun Xiaowen Tang Xiaohui Hu Source Type: research

Quality of life in patients with nonvalvular atrial fibrillation treated with oral anticoagulants
CONCLUSION: Patients treated with DOACs report a slightly better quality of life than those treated with VKAs.PMID:33631081 | DOI:10.1080/16078454.2021.1892329 (Source: Hematology)
Source: Hematology - February 25, 2021 Category: Hematology Authors: Miren Gabilondo Jes ús Loza Angel Pereda Ohiane Caballero Nerea Zamora Ania Gorostiza Javier Mar Source Type: research

Persistence to hypomethylating agents and clinical and economic outcomes among patients with myelodysplastic syndromes
Hematology. 2021 Dec;26(1):261-270. doi: 10.1080/16078454.2021.1889161.ABSTRACTOBJECTIVES: To evaluate hypomethylating agent (HMA) persistence in patients with myelodysplastic syndromes (MDS), and examine its association with healthcare resource utilization (HRU) and progression to acute myeloid leukemia (AML).METHODS: A total of 2,400 adults diagnosed with MDS initiating HMAs were included from IBM MarketScan databases during 1/1/2011-3/31/2018. The index date was HMA initiation following MDS diagnosis. Patients were classified according to their persistence status by the end of a fixed 'landmark period' of 4 months post-...
Source: Hematology - February 25, 2021 Category: Hematology Authors: Wendy Y Cheng Ambika Satija Hoi Ching Cheung Kala Hill Tim Wert Fran çois Laliberté Patrick Lefebvre Source Type: research

Myelomonocytic differentiation of leukemic blasts accompanied by differentiation syndrome in a case of < em > FLT3 < /em > -ITD-positive AML treated with gilteritinib
We report a case of relapsed AML with FLT3-ITD that was treated with gilteritinib. Analysis of the FLT3-ITD variant allele frequency (VAF) revealed that FLT3-ITD VAF was not decreased despite achievement of complete remission with incomplete hematologic recovery. Remarkable increases of monocytes and granulocytes accompanied by differentiation syndrome were observed at 6 months after the initiation of gilteritinib treatment. Intermittent chemotherapy with low-dose cytarabine and mitoxantrone was effective for reducing myelomonocytosis and resolving differentiation syndrome.PMID:33631087 | DOI:10.1080/16078454.2021.1889111 (Source: Hematology)
Source: Hematology - February 25, 2021 Category: Hematology Authors: Takeshi Kondo Masahiro Onozawa Shinichi Fujisawa Shinpei Harada Reiki Ogasawara Koh Izumiyama Makoto Saito Masanobu Morioka Akio Mori Takanori Teshima Source Type: research

Safety and efficacy of different doses of anthracyclines combined with arsenic trioxide and all-trans retinoic acid in the treatment of de novo acute promyelocytic leukemia
Hematology. 2021 Dec;26(1):271-276. doi: 10.1080/16078454.2021.1889159.ABSTRACTOBJECTIVES: The purpose of this study was to evaluate the efficacy and safety of different doses of anthracyclines combined with arsenic trioxide (ATO) and all-trans retinoic acid (ATRA) for induction in newly diagnosed acute promyelocytic leukemia (APL).METHODS: One hundred and forty patients were included between January 2011 and December 2017. Seventy patients received low dose anthracycline, ATO and ATRA for induction chemotherapy; and other seventy patients received standard dose anthracycline, ATO and ATRA for induction chemotherapy.RESULT...
Source: Hematology - February 25, 2021 Category: Hematology Authors: Yaxue Wu Peng Ke Haixia Zhou Depei Wu Suning Chen Huiying Qiu Yue Han Caixia Li Xiao Ma Aining Sun Xiaowen Tang Xiaohui Hu Source Type: research

Quality of life in patients with nonvalvular atrial fibrillation treated with oral anticoagulants
CONCLUSION: Patients treated with DOACs report a slightly better quality of life than those treated with VKAs.PMID:33631081 | DOI:10.1080/16078454.2021.1892329 (Source: Hematology)
Source: Hematology - February 25, 2021 Category: Hematology Authors: Miren Gabilondo Jes ús Loza Angel Pereda Ohiane Caballero Nerea Zamora Ania Gorostiza Javier Mar Source Type: research

Persistence to hypomethylating agents and clinical and economic outcomes among patients with myelodysplastic syndromes
Hematology. 2021 Dec;26(1):261-270. doi: 10.1080/16078454.2021.1889161.ABSTRACTOBJECTIVES: To evaluate hypomethylating agent (HMA) persistence in patients with myelodysplastic syndromes (MDS), and examine its association with healthcare resource utilization (HRU) and progression to acute myeloid leukemia (AML).METHODS: A total of 2,400 adults diagnosed with MDS initiating HMAs were included from IBM MarketScan databases during 1/1/2011-3/31/2018. The index date was HMA initiation following MDS diagnosis. Patients were classified according to their persistence status by the end of a fixed 'landmark period' of 4 months post-...
Source: Hematology - February 25, 2021 Category: Hematology Authors: Wendy Y Cheng Ambika Satija Hoi Ching Cheung Kala Hill Tim Wert Fran çois Laliberté Patrick Lefebvre Source Type: research

Myelomonocytic differentiation of leukemic blasts accompanied by differentiation syndrome in a case of < em > FLT3 < /em > -ITD-positive AML treated with gilteritinib
We report a case of relapsed AML with FLT3-ITD that was treated with gilteritinib. Analysis of the FLT3-ITD variant allele frequency (VAF) revealed that FLT3-ITD VAF was not decreased despite achievement of complete remission with incomplete hematologic recovery. Remarkable increases of monocytes and granulocytes accompanied by differentiation syndrome were observed at 6 months after the initiation of gilteritinib treatment. Intermittent chemotherapy with low-dose cytarabine and mitoxantrone was effective for reducing myelomonocytosis and resolving differentiation syndrome.PMID:33631087 | DOI:10.1080/16078454.2021.1889111 (Source: Hematology)
Source: Hematology - February 25, 2021 Category: Hematology Authors: Takeshi Kondo Masahiro Onozawa Shinichi Fujisawa Shinpei Harada Reiki Ogasawara Koh Izumiyama Makoto Saito Masanobu Morioka Akio Mori Takanori Teshima Source Type: research

Safety and efficacy of different doses of anthracyclines combined with arsenic trioxide and all-trans retinoic acid in the treatment of de novo acute promyelocytic leukemia
Hematology. 2021 Dec;26(1):271-276. doi: 10.1080/16078454.2021.1889159.ABSTRACTOBJECTIVES: The purpose of this study was to evaluate the efficacy and safety of different doses of anthracyclines combined with arsenic trioxide (ATO) and all-trans retinoic acid (ATRA) for induction in newly diagnosed acute promyelocytic leukemia (APL).METHODS: One hundred and forty patients were included between January 2011 and December 2017. Seventy patients received low dose anthracycline, ATO and ATRA for induction chemotherapy; and other seventy patients received standard dose anthracycline, ATO and ATRA for induction chemotherapy.RESULT...
Source: Hematology - February 25, 2021 Category: Hematology Authors: Yaxue Wu Peng Ke Haixia Zhou Depei Wu Suning Chen Huiying Qiu Yue Han Caixia Li Xiao Ma Aining Sun Xiaowen Tang Xiaohui Hu Source Type: research

Quality of life in patients with nonvalvular atrial fibrillation treated with oral anticoagulants
CONCLUSION: Patients treated with DOACs report a slightly better quality of life than those treated with VKAs.PMID:33631081 | DOI:10.1080/16078454.2021.1892329 (Source: Hematology)
Source: Hematology - February 25, 2021 Category: Hematology Authors: Miren Gabilondo Jes ús Loza Angel Pereda Ohiane Caballero Nerea Zamora Ania Gorostiza Javier Mar Source Type: research

Persistence to hypomethylating agents and clinical and economic outcomes among patients with myelodysplastic syndromes
Hematology. 2021 Dec;26(1):261-270. doi: 10.1080/16078454.2021.1889161.ABSTRACTOBJECTIVES: To evaluate hypomethylating agent (HMA) persistence in patients with myelodysplastic syndromes (MDS), and examine its association with healthcare resource utilization (HRU) and progression to acute myeloid leukemia (AML).METHODS: A total of 2,400 adults diagnosed with MDS initiating HMAs were included from IBM MarketScan databases during 1/1/2011-3/31/2018. The index date was HMA initiation following MDS diagnosis. Patients were classified according to their persistence status by the end of a fixed 'landmark period' of 4 months post-...
Source: Hematology - February 25, 2021 Category: Hematology Authors: Wendy Y Cheng Ambika Satija Hoi Ching Cheung Kala Hill Tim Wert Fran çois Laliberté Patrick Lefebvre Source Type: research

Myelomonocytic differentiation of leukemic blasts accompanied by differentiation syndrome in a case of < em > FLT3 < /em > -ITD-positive AML treated with gilteritinib
We report a case of relapsed AML with FLT3-ITD that was treated with gilteritinib. Analysis of the FLT3-ITD variant allele frequency (VAF) revealed that FLT3-ITD VAF was not decreased despite achievement of complete remission with incomplete hematologic recovery. Remarkable increases of monocytes and granulocytes accompanied by differentiation syndrome were observed at 6 months after the initiation of gilteritinib treatment. Intermittent chemotherapy with low-dose cytarabine and mitoxantrone was effective for reducing myelomonocytosis and resolving differentiation syndrome.PMID:33631087 | DOI:10.1080/16078454.2021.1889111 (Source: Hematology)
Source: Hematology - February 25, 2021 Category: Hematology Authors: Takeshi Kondo Masahiro Onozawa Shinichi Fujisawa Shinpei Harada Reiki Ogasawara Koh Izumiyama Makoto Saito Masanobu Morioka Akio Mori Takanori Teshima Source Type: research

Safety and efficacy of different doses of anthracyclines combined with arsenic trioxide and all-trans retinoic acid in the treatment of de novo acute promyelocytic leukemia
Hematology. 2021 Dec;26(1):271-276. doi: 10.1080/16078454.2021.1889159.ABSTRACTOBJECTIVES: The purpose of this study was to evaluate the efficacy and safety of different doses of anthracyclines combined with arsenic trioxide (ATO) and all-trans retinoic acid (ATRA) for induction in newly diagnosed acute promyelocytic leukemia (APL).METHODS: One hundred and forty patients were included between January 2011 and December 2017. Seventy patients received low dose anthracycline, ATO and ATRA for induction chemotherapy; and other seventy patients received standard dose anthracycline, ATO and ATRA for induction chemotherapy.RESULT...
Source: Hematology - February 25, 2021 Category: Hematology Authors: Yaxue Wu Peng Ke Haixia Zhou Depei Wu Suning Chen Huiying Qiu Yue Han Caixia Li Xiao Ma Aining Sun Xiaowen Tang Xiaohui Hu Source Type: research

A 10-year cohort study of 175 primary gastrointestinal lymphoma cases in Thailand: clinical features and outcomes in the immunochemotherapy era
CONCLUSIONS: The stomach was the most common site of lymphoma involvement in the GI tract, with DLBCL accounting for the highest proportion of those patients. The long-term survival outcome was significantly improved in patients with good performance status and rituximab exposure. Trial registrationNot applicable.PMID:33618613 | DOI:10.1080/16078454.2021.1889160 (Source: Hematology)
Source: Hematology - February 23, 2021 Category: Hematology Authors: Weerapat Owattanapanich Theera Ruchutrakool Tawatchai Pongpruttipan Monthira Maneerattanaporn Source Type: research

Ethnic differences in acute promyelocytic leukaemia between New Zealand Polynesian and European patients.
Authors: Varghese C, Liu VY, Immanuel T, Chien N, Green T, Chan G, Theakston E, Kalev-Zylinska M Abstract Ethnic differences in haematologic malignancies remain poorly elucidated, hence research in this area is important. This was a retrospective study into potential ethnic disparity in the presentation and outcomes of acute promyelocytic leukaemia (APL) between New Zealand (NZ) Polynesian and European patients. Data were analysed for patients treated at Auckland City Hospital (ACH; n = 55) and recorded in the New Zealand Cancer Registry (NZCR; n = 173), both for the period 2000-2017. We...
Source: Hematology - February 18, 2021 Category: Hematology Tags: Hematology Source Type: research

Allogeneic hematopoietic cell transplantation using fludarabine plus myeloablative busulfan and melphalan confers promising survival in high-risk hematopoietic neoplasms: a single-center retrospective analysis.
CONCLUSION: These results suggest that our FBM regimen can be applied to allo-HCT using various graft types and yields acceptable outcomes with relatively low non-relapse mortality in both myeloid and lymphoid neoplasms. Also, we observed a promising survival in the group of patients with high-risk diseases, warranting more accumulation of patients and longer follow-up. PMID: 33594942 [PubMed - in process] (Source: Hematology)
Source: Hematology - February 18, 2021 Category: Hematology Tags: Hematology Source Type: research

The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
This study aims to explore clinical and molecular factors that can help determine the prognosis of those patients and their choice of PRT. METHODS: We retrospectively analyzed 28 patients with NPM1mut-negCEBPAdm-negFLT3-ITDneg AML who received induction chemotherapy and achieved CR1. For PRT, 17 patients received post-remission chemotherapy (PR-CT) and 11 patients received allogeneic hematopoietic stem cell transplantation (allo-HSCT). RESULTS: For patients with NPM1mut-negCEBPAdm-negFLT3-ITDneg AML, multivariate analysis indicated that allo-HSCT and negative minimal residual disease (MRDneg) before PRT were favora...
Source: Hematology - February 18, 2021 Category: Hematology Tags: Hematology Source Type: research

High expression of CD56 may be associated with favorable overall survival in intermediate-risk acute myeloid leukemia.
CONCLUSIONS: The prognostic value of CD56 expression in IR-AML may need to be comprehensively evaluated based on different detection methods, age stratification, countries, treatment options, and other factors. If confirmed, CD56 may be a biomarker for further risk stratification for IR-AML patients. PMID: 33594945 [PubMed - in process] (Source: Hematology)
Source: Hematology - February 18, 2021 Category: Hematology Tags: Hematology Source Type: research

A cost-effectiveness analysis of the prophylaxis versus on-demand regimens in severe hemophilia A patients under 12 years old in southern Iran.
CONCLUSION: Prophylaxis regimen showed the lower costs and higher effectiveness and utility in comparison with the on-demand regimen. It is recommended that prophylaxis should be considered as the standard care for treatment of hemophilic patients. PMID: 33594948 [PubMed - in process] (Source: Hematology)
Source: Hematology - February 18, 2021 Category: Hematology Tags: Hematology Source Type: research

Anticoagulation and bone marrow biopsy: is it safe to proceed?
CONCLUSION: Withholding anticoagulation prior to BM biopsy is not routinely recommended. Instead, assessment and optimization of bleeding risk factors should be done on a patient by patient basis. PMID: 33594950 [PubMed - in process] (Source: Hematology)
Source: Hematology - February 18, 2021 Category: Hematology Tags: Hematology Source Type: research

Hematologic autoimmune disorders in the course of COVID-19: a systematic review of reported cases.
CONCLUSION: The current study would help us to always consider an autoimmune etiology for cases with abnormal hematologic finding which further lead to an appropriate treatment of the patients, especially when the symptoms present in about 1-2 weeks after the first manifestation of the infection symptoms. Maybe, at least in this pandemic, it should be recommended to evaluate patients with unexpected and unexplained decrease in their hemoglobulin or platelet count for COVID-19. Another challenging issue is the treatment options. Given the multiorgan involvement and multifaceted nature of the infection, an individualized app...
Source: Hematology - February 18, 2021 Category: Hematology Tags: Hematology Source Type: research

Management of sickle cell disease: current practices and challenges in a northeastern region of the Democratic Republic of the Congo.
CONCLUSION: Standard-care practices for SCD patients in Kisangani are insufficient. The Congolese government should regard this disease as a health priority and consider actions to improve its management. PMID: 33594960 [PubMed - in process] (Source: Hematology)
Source: Hematology - February 18, 2021 Category: Hematology Tags: Hematology Source Type: research

HOTAIR suppresses PTEN via DNMT3b and confers drug resistance in acute myeloid leukemia.
CONCLUSION: HOTAIR suppresses PTEN through up-regulating DNMT3b-dependent way and confers ADM resistance in AML. PMID: 33538241 [PubMed - in process] (Source: Hematology)
Source: Hematology - February 6, 2021 Category: Hematology Tags: Hematology Source Type: research

Long non-coding RNA ANRIL and its target microRNAs (microRNA-34a, microRNA-125a and microRNA-186) relate to risk stratification and prognosis in multiple myeloma.
CONCLUSION: LncRNA ANRIL and its target miRNAs might serve as biomarkers for assisting with personalized treatment and prognosis improvement of MM. PMID: 33528317 [PubMed - in process] (Source: Hematology)
Source: Hematology - February 4, 2021 Category: Hematology Tags: Hematology Source Type: research

Hematopoietic stem cell transplantation for inherited bone marrow failure syndromes: alternative donor and disease-specific conditioning regimen with unmanipulated grafts.
Conclusion: HSCT using alternative donors with unmanipulated grafts and disease-specific conditioning regimens for IBMFS patients shows promising survival. PMID: 33491597 [PubMed - in process] (Source: Hematology)
Source: Hematology - January 27, 2021 Category: Hematology Tags: Hematology Source Type: research

Myeloid/lymphoid neoplasm with CEP110-FGFR1 fusion: An analysis of 16 cases show common features and poor prognosis.
Conclusion: FGFR1 and RUNX1 may be potential therapeutic targets for clinical trials. More accumulation of cases is also needed to determine whether allo-HSCT could be an optimal approach. PMID: 33491601 [PubMed - in process] (Source: Hematology)
Source: Hematology - January 27, 2021 Category: Hematology Tags: Hematology Source Type: research

Association of cytotoxic T-lymphocyte antigen-4 (CTLA-4) single nucleotide polymorphism in donors with clinical outcome after allogeneic hematopoietic stem cell transplantation: a meta-analysis.
CONCLUSIONS: The present meta-analysis suggests that donors with CT60 G allele might be associated with worse OS but reduced severe aGVHD occurrence, while patients transplanted from donors with GG genotype at position of +49 are more likely to suffer from cGVHD. PMID: 33491603 [PubMed - in process] (Source: Hematology)
Source: Hematology - January 27, 2021 Category: Hematology Tags: Hematology Source Type: research

Analysis of the influencing factors related to liver and cardiac iron overload in MDS patients detected by MRI in the real world.
CONCLUSION: These results showed special attention should be paid to these related influencing factors of liver and cardiac T2* expression when we evaluated iron overload and detected the efficacy of ICT in MDS patients. PMID: 33491605 [PubMed - in process] (Source: Hematology)
Source: Hematology - January 27, 2021 Category: Hematology Tags: Hematology Source Type: research

Next-generation sequencing reveals gene mutations landscape and clonal evolution in patients with acute myeloid leukemia.
CONCLUSION: NGS techniques is a useful tool for discovering related gene mutations and clonal evolution in AML genomes, leading to novel targeted therapeutic approaches that could improve patients outcomes. PMID: 33491606 [PubMed - in process] (Source: Hematology)
Source: Hematology - January 27, 2021 Category: Hematology Tags: Hematology Source Type: research

Hodgkin lymphoma involving extranodal sites in head and neck: report of twenty-nine cases and review of three-hundred and fifty-seven cases.
CONCLUSION: This largest report showed that HL involving extranodal head and neck sites is not very uncommon and has excellent prognosis. PMID: 33478377 [PubMed - in process] (Source: Hematology)
Source: Hematology - January 24, 2021 Category: Hematology Tags: Hematology Source Type: research

Impact of pre-transplant use of antibiotics on the graft-versus-host disease in adult patients with hematological malignancies.
CONCLUSION: Pre-transplant use of glycopeptide tends to increase the incidence of extensive cGVHD. PMID: 33459581 [PubMed - in process] (Source: Hematology)
Source: Hematology - January 21, 2021 Category: Hematology Tags: Hematology Source Type: research

Assessment of Lebanese healthcare professionals' awareness on acquired haemophilia: a cross-sectional study.
CONCLUSIONS: Appropriate treatment and diagnosis are essential when dealing with AHA. Knowledge gaps exist in the clinical practice when dealing with patients who have AHA. This study shows the need for increasing awareness about AHA among HCPs in Lebanon regarding the diagnosis and treatment of this disorder. PMID: 33427128 [PubMed - in process] (Source: Hematology)
Source: Hematology - January 12, 2021 Category: Hematology Tags: Hematology Source Type: research

A five-year retrospective study of treatment outcomes using the L-asparaginase-based regimen as a first-line chemotherapy protocol for patients diagnosed with extranodal NK/T-cell lymphoma, nasal-type, in Thailand.
CONCLUSIONS: L-asparaginase-based regimens offer a good outcome as a front-line treatment for ENKTL. PMID: 33427594 [PubMed - as supplied by publisher] (Source: Hematology)
Source: Hematology - January 12, 2021 Category: Hematology Tags: Hematology Source Type: research

Comparison of autologous and allogeneic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Conclusions: Auto-SCT with maintenance therapy after HSCT appears to be an attractive treatment option for patients with Ph+ ALL especially for those whose s3CMR was kept up to transplantation. For non-s3CMR patients, allogeneic transplantation may be more effective from lower relapse. PMID: 33402056 [PubMed - in process] (Source: Hematology)
Source: Hematology - January 8, 2021 Category: Hematology Tags: Hematology Source Type: research

Analysis of gamma-glutamyltransferase in acute promyelocytic leukemia patients undergoing arsenic trioxide treatment.
CONCLUSION: Single elevation in GGT without elevated aminotransferases can't be identified as hepatotoxicity, and the elevated levels of GGT are associated with increasing leukocyte counts. Continue single-agent ATO without prophylactic hepatoprotective agents is recommended in APL patients with single elevation in GGT, in order to maintain ATO effect. PMID: 33402059 [PubMed - in process] (Source: Hematology)
Source: Hematology - January 8, 2021 Category: Hematology Tags: Hematology Source Type: research

Pretreatment grade 4 thrombocytopenia is an independent prognostic factor in adult acute lymphoblastic leukemia: an extended analysis of a single-center retrospective study.
Conclusion: Grade 4 thrombocytopenia was a negative prognostic factor for both overall survival and disease-free survival of adults with acute lymphoblastic leukemia. PMID: 33357100 [PubMed - in process] (Source: Hematology)
Source: Hematology - December 29, 2020 Category: Hematology Tags: Hematology Source Type: research

Up-regulated miR-155 is associated with poor prognosis in childhood acute lymphoblastic leukemia and promotes cell proliferation targeting ZNF238.
CONCLUSION: Our results propose that miR-155 is in association with poor prognosis of childhood ALL. Furthermore, miR-155 could promote cell proliferation targeting ZNF238. PMID: 33357126 [PubMed - in process] (Source: Hematology)
Source: Hematology - December 29, 2020 Category: Hematology Tags: Hematology Source Type: research

Prognostic value of RASD1 transcript levels in adult Philadelphia-negative B-cell acute lymphoblastic leukemia.
Authors: Lu RQ, Wu LX, Zhang J, Qin YZ, Liu YR, Lai YY, Jiang H, Chang YJ, Ruan GR, Huang XJ Abstract OBJECTIVES: Ras-related dexamethasone-induced 1 (RASD1) is abnormally expressed in many solid cancers. However, its potential role in adults with B-cell acute lymphoblastic leukemia (B-ALL) is unclear. Therefore, we aim to clarify the abnormal expression of the tumor-associated biomarker, RASD1, as a potential target for diagnosis and prognosis in adult Philadelphia-negative B-ALL. METHODS: The expression of RASD1 was detected with RT-qPCR in 92 adults with de novo Ph-negative B-ALL and 40 healthy controls. The...
Source: Hematology - December 29, 2020 Category: Hematology Tags: Hematology Source Type: research

The association between pre-transfusion hemoglobin levels and thalassemia complications.
CONCLUSIONS: Lower Hb level was associated with more frequent complications in both TDT and NTDT patients. The Hb cutoff levels to predict these complications were identified. PMID: 33357151 [PubMed - in process] (Source: Hematology)
Source: Hematology - December 29, 2020 Category: Hematology Tags: Hematology Source Type: research

Efficacy and safety of eltrombopag in the treatment of Chinese children with chronic immune thrombocytopenia.
Authors: Chen M, Fang JP, Zhou CX, Li XY, Lin SF, Xu LH Abstract OBJECTIVES: Our aim is to evaluate initial efficacy, safety, and durable response of eltrombopag in the treatment of Chinese children with chronic immune thrombocytopenia (cITP). METHODS: This was a retrospective, single-center cohort study including 30 pediatric patients with cITP administered eltrombopag between 1 July 2017 and 1 January 2019. Patients with at least 12 weeks of eltrombopag treatment and available follow-up data were included. Initial response rate, durable response rate, bleeding events, and adverse events were assessed during t...
Source: Hematology - December 29, 2020 Category: Hematology Tags: Hematology Source Type: research

The prognostic impact of abnormally expressed, long noncoding RNAs in acute myeloid leukemia: a meta-analysis.
Conclusion: Abnormally expressed lncRNAs are significantly related to worse prognoses of AML patients and might serve as potential prognostic markers to predict the prognosis of AML patients. PMID: 33346694 [PubMed - in process] (Source: Hematology)
Source: Hematology - December 23, 2020 Category: Hematology Tags: Hematology Source Type: research

Prognostic effect of RUNX1 mutations in myelodysplastic syndromes: a meta-analysis.
Authors: He W, Zhao C, Hu H Abstract OBJECTIVES: RUNX1 mutations have been widely found in patients with myelodysplastic syndrome (MDS). Majority of reports revealed that RUNX1 mutations are associated with a poor prognosis. However, discrepancies still remain. The results of univariate analysis were not confirmed in multivariate analysis in some cases. Therefore, we performed a meta-analysis to assess the prognostic effect of RUNX1 mutations in MDS. METHODS: We extracted data from qualified studies that were searched from PubMed, Embase and the Cochrane Library. Hazard ratios (HRs) and their 95% confidence int...
Source: Hematology - December 16, 2020 Category: Hematology Tags: Hematology Source Type: research

Efficacy and safety of four-factor prothrombin complex concentrate fixed, weight-based dosing for reversal of warfarin anticoagulation.
Authors: Endres K, St Bernard R, Chin-Yee I, Hsia C, Lazo-Langner A Abstract BACKGROUND: Four-factor prothrombin complex concentrate (4F-PCC) is widely used for urgent reversal of anticoagulation with warfarin, but the optimal 4F-PCC dosing approach is unknown. Herein, we sought to determine the efficacy of a novel fixed, weight-based dosing nomogram. METHODS: We retrospectively studied consecutive adult patients receiving fixed, weight-based 4F-PCC dosing for warfarin reversal between 30 April 2009 and 31 December 2010. The primary outcome was reversal of warfarin anticoagulation, defined as INR ≤1.5 within...
Source: Hematology - December 16, 2020 Category: Hematology Tags: Hematology Source Type: research